Boston Scientific India announced that it has launched the next generation asthma therapy in the country to address the needs of patients with severe persistent, drug-resistant asthma. "We have launched bronchial thermoplasty (BT) therapy indicated for the treatment of severe, persistent, drug-resistant asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long acting beta agonists. The first BT procedure was performed in Royal Care Hospital, Coimbatore today," a company statement said here. "There are over 18 million estimated asthmatics in the country.
Our therapy holds great promise to help address this need gap. We have sufficient evidence that shows Bronchial Thermoplasty is an effective therapeutic option for patients with severe persistent, drug-resistant asthma," said Boston Scientific in India vice president and managing director Prabal Chakraborty.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)